Genes2Me has announced the launch of its Rapi-Q- Point of Care RTPCR solution for 1 to 8 samples of different diseases, which is easy to use and gives faster results in less than 45 minutes. Backed by a powerful software analysis function, the CE-IVD marked POC solution delivers performance, sensitivity, and stable detection, the company said in a statement on Monday.
Rapi-Q point of care RTPCR solution has been approved by ICMR, The system can process upto 8 samples in a single run. Rapi-Q is ideal for detecting several diseases, including tuberculosis, HPV, 3H, HIV, HCV and HBV, tropical fever and respiratory ailments.
Genes2Me Founder and CEO, Mr Neeraj Gupta says, "Rapi-Q is the choice of care for hospitals, blood banks, health clinics, research laboratories, and airports. Today, large volumes of samples need to be tested in clinical laboratories; thus, it takes a long time for results to be interpreted. We understood the need for point-of-care testing so that tests could be performed at the patient's location and beyond the laboratories. The test provides much faster access to accurate test results for several diseases at once, allowing for more rapid clinical decision-making and more-appropriate treatments and interventions".
Rapi-Q comprises an eight-well block design with four fluorescent channels that can perform singleplex and multiplex for qualitative/ quantitative analysis, melting curve analysis, genotyping, etc., the statement said.
The RTPCR system provides a convenient format for highly sensitive and specific diseases. Because of its portability and evaluation of several samples at once, Rapi-Q can detect infectious diseases in remote or resource-limited areas that do not have access to diagnostic labs, the statement read further.